METEOR Trial: Quality-of-Life Outcomes in Metastatic Kidney Cancer
Patients with metastatic renal cell carcinoma with bone metastases treated with cabozantinib had a clear extension of time to deterioration, when quality of life was assessed in comparison to everolimus treatment, in the phase III METEOR trial. This study, led by David Cella, PhD, of Northwestern University Feinberg School of Medicine, showed cabozantinib to have maintained a similar quality of life compared with everolimus. However, cabozantinib was associated with worse nausea and diarrhea, and everolimus, with worse shortness of breath. These results were published in the Journal of Clinical Oncology.
The 658 previously treated patients with advanced renal cell carcinoma were randomly assigned 1:1 into groups to receive either cabozantinib or everolimus treatment. Patients were asked to complete a 19-item Functional Assessment of Cancer Therapy–Kidney Symptom Index, as well as a subset of this questionnaire focused on disease-related symptoms and the five-level EuroQol at baseline and throughout the study. The completion rate of these questionnaires remained greater than 75% through week 48 in both arms. There was no difference found over time for any of the questionnaires in either arm.
Although the trial showed that quality of life “was generally maintained over time to a similar extent in both the cabozantinib and everolimus arms,” the authors concluded that cabozantinib generally extended time to deterioration overall, particularly in those with bone metastases.